A Profile of Adult Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia Patients According to Pneumococcal Vaccination Status

Author:

Morales-Suárez-Varela María12ORCID,Toledo Diana23ORCID,Fernández-Sierra María Amelia4,Liébana María34,Rubiera Gerardo5,Navarro Gema678,Prados Concepción9,Chamarro Judith10,Peraita-Costa Isabel12,Domínguez Angela23ORCID,

Affiliation:

1. Research Group in Social and Nutritional Epidemiology, Pharmacoepidemiology and Public Health, Department of Preventive Medicine and Public Health, Food Sciences, Toxicology and Forensic Medicine, Faculty of Pharmacy, Universitat de València, Av. Vicent Andrés Estelles s/n, Burjassot, 46100 València, Spain

2. Biomedical Research Center in Epidemiology and Public Health Network (CIBERESP), Carlos III Health Institute, Av. Monforte de Lemos 3-5 Pabellón 11 Planta 0, 28029 Madrid, Spain

3. Department of Medicine, Faculty of Medicine and Health Sciences, Universitat de Barcelona, C/Casanova 143, 08036 Barcelona, Spain

4. Hospital Universitario Virgen de las Nieves, Av. de las Fuerzas Armadas 2, 18014 Granada, Spain

5. Hospital Universitario de Cabueñes, C/de Los Prados 395, 33394 Gijón, Spain

6. Parc Tauli Hospital Universitari, C/Parc Taulí 1, 08208 Sabadell, Spain

7. Institut d’Investigació i Innovació Parc Tauli (I3PT-CERCA), Plaça Torre de l’Aigua s/n, 08208 Sabadell, Spain

8. Department of Paediatrics, Obstetrics and Gynaecology and Preventive Medicine and Public Health, Faculty of Medicine, Universitat Autònoma de Barcelona, Av. Can Domènech Edifici M, 08193 Bellaterra, Spain

9. Hospital Universitario La Paz, P.º de la Castellana 261, 28046 Madrid, Spain

10. Hospital Universitario de Navarra, C/Irunlarrea 3, 31008 Pamplona, Spain

Abstract

Certain patient profile characteristics, such as preexisting medical conditions, can modify the risk of developing SARS-CoV-2 pneumonia among adults vaccinated and not vaccinated against pneumococcal disease. This retrospective cohort study aimed to quantify the risk of pneumonia caused by SARS-CoV-2 among individuals from 15 to 64 years old with and without pneumococcal vaccination in Spain during the 2020–2021 influenza season and establish a risk profile of patients more likely to develop SARS-CoV-2 pneumonia. Data (demographic information, patient medical history, and lifestyle habits) were gathered both directly from the patient via personal interview and by reviewing electronic medical records. In an adjusted analysis for pneumococcal vaccinated patients, visits to hospital outpatient clinics were protective while visits to primary health care services, being widowed, obese, and not using masks in outdoor open spaces were identified as risk factors. For patients who had not received a pneumococcal vaccine, visits to hospital outpatient clinics were protective, while being overweight or obese, alcohol consumption, and not using masks in outdoor open spaces were identified as risk factors. Concerning comorbidities, in the pneumococcal vaccinated group none were found to be protective but having diabetes or other respiratory diseases were identified as risk factors. In the unvaccinated group, undergoing immunosuppressive treatment and having metastatic tumors were protective factors, while cerebrovascular disease and obesity with a BMI ≥ 40 were risk factors. A similar risk profile for developing SARS-CoV-2 pneumonia in pneumococcal vaccinated and non-vaccinated individuals was found. Generally, vaccinated individuals had a lower risk of developing SARS-CoV-2. The findings suggest that vaccination against S. pneumoniae could prevent and reduce SARS-CoV-2 pneumonia. Additionally, this study has identified individuals with other medical conditions, such as obesity, underweight, diabetes, and a history of respiratory diseases, who are at an increased risk of developing SARS-CoV-2 pneumonia and could benefit from vaccination and supervision.

Funder

Instituto de Salud Carlos III

Catalan Agency for the Management of Grants for University Research

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference29 articles.

1. Viral Pneumonia. COVID-19 Pneumonia;Allende;Medicine,2022

2. Heneghan, C., Pluddemann, A., and Mahtani, K.R. (2020). Differentiating Viral from Bacterial Pneumonia, Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University of Oxford. Technical Report.

3. Pneumococcal Infection in Adults: Burden of Disease;Drijkoningen;Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.,2014

4. Polysaccharide Conjugate Vaccine Against Pneumococcal Pneumonia in Adults;Bonten;N. Engl. J. Med.,2015

5. American Lung Association (2023). What Causes Pneumonia?, American Lung Association.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3